{"id":390661,"date":"2018-06-04T00:00:00","date_gmt":"2018-06-04T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthim0015-2018-biopharma-atopic-dermatitis-atopic-eczema-emerging-therapies-dupixent-dupilumab-us-wave-3-2018\/"},"modified":"2026-05-12T11:38:23","modified_gmt":"2026-05-12T11:38:23","slug":"emthim0015-2018-biopharma-atopic-dermatitis-atopic-eczema-emerging-therapies-dupixent-dupilumab-us-wave-3-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/emthim0015-2018-biopharma-atopic-dermatitis-atopic-eczema-emerging-therapies-dupixent-dupilumab-us-wave-3-2018\/","title":{"rendered":"Atopic Dermatitis\/Atopic Eczema | Emerging Therapies | Dupixent (dupilumab) | US | Wave 3 | 2018"},"content":{"rendered":"<p><strong>Atopic Dermatitis | Emerging Therapies | Dupixent | US <\/strong>is a three-wave series that tracks the introduction of Sanofi\/Regeneron\u2019s Dupixent for the treatment of AD. The series is based on primary research data collected 1, 6, and 12 months after Dupixent\u2019s launch. Along with awareness of, familiarity with, and perceptions related to Dupixent, this research assesses the trial and use, including anticipated future trends, of Dupixent. We also explore Sanofi\/Regeneron\u2019s promotional efforts, prescriber and nonprescriber profiles, and benchmarking against other previously launched immune agents.<\/p>\n<p><strong>What you will learn in this content:<\/strong><\/p>\n<ul>\n<li>What are U.S. dermatologists\u2019 awareness of and familiarity with Dupixent, and what are their perceptions of the product?<\/li>\n<li>To which patients is Dupixent being prescribed, what are the reasons for prescribing it, and how satisfied are dermatologists with it?<\/li>\n<li>What promotional messages and activities are Sanofi and Regeneron using to support Dupixent\u2019s launch?<\/li>\n<li>How do prescribers and nonprescribers compare across key metrics?<\/li>\n<li>How do the trial and adoption of Dupixent compare with the trial and adoption of other recent product launches for AD?<\/li>\n<\/ul>\n<p><strong>Methodology:<\/strong> ~75 U.S. dermatologists completed a 30-minute online quantitative survey with several open-ended questions for qualitative feedback.<\/p>\n<p><strong>Key drugs:<\/strong> Dupixent<\/p>\n<p><strong>Key companies:<\/strong> Sanofi, Regeneron<\/p>\n<p><strong>Related reports: <\/strong>Atopic Dermatitis Disease Landscape and Forecast, Atopic Dermatitis Unmet Need, Access and Reimbursement \u2013 Atopic Dermatitis (US), Access and Reimbursement \u2013 Atopic Dermatitis (EU), Atopic Dermatitis Emerging Therapy Launch Tracking Eucrisa<\/p>\n","protected":false},"template":"","class_list":["post-390661","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-product-emerging-therapies","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390661","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390661\/revisions"}],"predecessor-version":[{"id":393785,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390661\/revisions\/393785"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390661"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}